Sharekhan

Lincoln Pharmaceuticals Ltd

Tue 29/04/2025,15:53:21 | NSE : LINCOLN

₹ 582.65-5.95 (-1.01%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 595.60

Previous Close

₹ 588.60

Volume

28939

Mkt Cap ( Rs. Cr)

₹1167.03

High

₹ 605.20

Low

₹ 576.90

52 Week High

₹ 979.50

52 Week Low

₹ 499.00

Book Value Per Share

₹ 319.16

Dividend Yield

0.30

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Lincoln Pharmaceuticals Ltd

Your Vote -

Buy

79.17%

Hold

16.67%

Sell

4.17%

79.17%

24 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

582.65

170

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

170

Option Chain

Analyzes market sentiment, predicts Lincoln Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Lincoln Pharmace - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

    23 Apr 2025, 3:48PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td
  • Lincoln Pharmace - Updates

    18 Apr 2025, 12:46PM Lincoln Pharmaceuticals Limited has informed the Exchange regarding ' Intimation Of Change In Email And Website Address Of MUFG Intime India Private L
  • Lincoln Pharmace - Disclosure under SEBI Takeover Regulations

    15 Apr 2025, 8:38PM Mahendrabhai Gulabdas Patel has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (S
  • Lincoln Pharmace has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    14 Apr 2025, 12:30PM As of March 2025, 49.78% is owned by Indian Promoters and 50.22% by Public. <p align=justify> Top five Promoters holding highest number of shares of L
  • Lincoln Pharmace - Disclosure under SEBI Takeover Regulations

    11 Apr 2025, 6:40PM Lincoln Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of Indi
  • Lincoln Pharmace - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    5 Apr 2025, 1:01PM Lincoln Pharmaceuticals Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation
  • Lincoln Pharmace - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    5 Apr 2025, 12:58PM Pursuant to provision of Regulation 74(5) of SEBI (Depository and Participant) Regulations, 2018, we hereby submit the confirmation certificate as rec
  • Lincoln Pharmace - General Updates

    28 Mar 2025, 6:18PM Lincoln Pharmaceuticals Limited has informed the Exchange about General Updates
  • Lincoln Pharmace - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015.

    28 Mar 2025, 6:08PM Dissemination of cautionary letter/mail dated 28.03.2025 received from National Stock Exchange of India Limited and BSE Limited.
  • Lincoln Pharmace - Trading Window-XBRL

    26 Mar 2025, 2:47PM LINCOLN PHARMACEUTICALS LIMITED has informed the Exchange about Closure of Trading Window
  • Lincoln Pharmace - Trading Window

    26 Mar 2025, 2:42PM Lincoln Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regul
  • Lincoln Pharmace - Reply to Clarification- Financial results

    7 Mar 2025, 2:15PM The Exchange had sought clarification from Lincoln Pharmaceuticals Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI
  • Lincoln Pharmace - Clarification - Financial Results

    4 Mar 2025, 5:54PM The Exchange has sought clarification from Lincoln Pharmaceuticals Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI
  • Lincoln Pharmace - Copy of Newspaper Publication

    14 Feb 2025, 12:05PM Lincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
  • Lincoln Pharmace - Integrated Filing- Financial

    13 Feb 2025, 1:11PM Integrated Filing (Financial) for the Quarter and Nine Months ended 31st December, 2024
  • Lincoln Pharmace - Financial Result Updates

    13 Feb 2025, 12:17PM Lincoln Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
  • Lincoln Pharmace - Board Meeting Outcome for OUTCOME OF THE BOARD MEETING

    13 Feb 2025, 12:17PM UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2024
  • Lincoln Pharmace - Integrated Filing (Financial)

    13 Feb 2025, 1:10PM Integrated Filing (Financials) for the Quarter and Nine Months ended 31st December, 2024.
  • Lincoln Pharmace - UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2024\r\n

    13 Feb 2025, 12:21PM UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED ON 31.12.2024\r\n
  • Lincoln Pharmace Q3 net profit down 25.93% at Rs 20.77 cr

    13 Feb 2025, 12:20PM The company reported standalone net profit of Rs 20.77 crore for the quarter ended December 31, 2024 as compared to Rs 28.04 crore in the same period
  • Lincoln Pharmace - Board Meeting Intimation

    5 Feb 2025, 11:27AM LINCOLN PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 13-Feb-2025 to inter-alia consider and approve the Unaudit
  • Lincoln Pharmace - Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Con

    5 Feb 2025, 11:16AM LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 ,inter alia, to cons
  • Lincoln Pharma

    3 Apr 2023 , 1:26PM ICRA reaffirms Lincoln Pharma's credit rating to A Stable due to long vintage of promoters, repeat orders, diversified products, and growing geographical footprint in India and surging share of exports to unregulated and semi regulated markets. Marginally positive for the stock.
  • Lincoln Pharmaceuticals gets nod from Australian Regulator, TGA

    8 Oct 2021 , 12:30PM Company plans to enter Australian markets soon with Dermatology, Gastro and Pain Mana ement roducts and ex nd radual
  • Lincoln Pharmaceuticals plans to launch Cephalosporin products soon

    21 Sep 2021 , 2:31PM Lincoln Pharmaceuticals plans to launch Cephalosporin products soon: acquires a plant in Mehsana, Gujarat
  • Lincoln Pharma launches Vitamin C+ Zinc tablets

    30 Jul 2020 , 2:20PM Lincoln Pharmaceuticals launches Vitamin C+ Zinc Tablets to boost immunity in the fight against CoVID-19'
  • Lincoln Pharma gets EU GMP approval

    19 May 2020 , 1:57PM Lincoln Pharmaceuticals receives European Union (EU) GMP approval
  • Lincoln Pharma receives nod to manufacture Hydroxychloroquine

    27 Apr 2020 , 11:51AM Lincoln Pharma gets nod from Food & Drug Control Administration, Gujarat to manufacture HCQ & HCQS tablets to fight COVID-19

Key fundamentals

Evaluate the intrinsic value of Lincoln Pharmaceuticals Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 593.9027 504.4716 434.921 365.0977 308.8478
Liabilities 593.9027 504.4716 434.921 365.0977 308.8478
Equity 20.0297 20.0297 20.0297 20 20
Gross Profit 99.9074 89.1668 95.4702 81.35 59.3688
Net Profit 93.3049 72.8994 69.355 60.4061 49.5636
Cash From Operating Activities 63.2445 39.1562 76.1831 71.41 70.71
NPM(%) 16.07 14.28 14.69 14.62 13.17
Revenue 580.5496 510.3088 472.0789 413.0552 376.0883
Expenses 480.6422 421.142 376.6087 331.7052 316.7195
ROE(%) 14.59 11.4 10.84 9.44 7.75

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
13 Sep 2024 1.8 18 0.31 572.75
15 Sep 2023 1.5 15 0.31 394.4
15 Sep 2022 1.5 15 0.31 283.8
16 Sep 2021 1.5 15 0.31 296.25
05 Mar 2020 1.5 15 0.31 177.55
19 Sep 2019 1.5 15 0.31 180.75
19 Sep 2018 1.5 15 0.31 216.05
21 Sep 2017 1.2 12 0.31 187.55
23 Sep 2016 1 10 0.31 150

Peers

Other companies within the same industry or sector that are comparable to Lincoln Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 840.85 0.23 11.87 335.93 1321.50 1.37
Lotus Eye Hospital and Institute Ltd 81.36 2.94 339.00 1224.07 14.01 0.61
Vaishali Pharma Ltd 13.72 -0.15 457.33 630.93 2.76 0.00
Astec Lifesciences Ltd 693.05 -1.61 0.00 1154.19 -687.11 0.00

Company Info

The Company was incorporated as a public limited company by converting partnership concern M/s. Lincoln Pharmaceuticals under Part IX of the Companies Act 1956. M/s.Lincoln Pharmaceuticals was established as a partnership firm on 18th January 1979 with Mr. Rajni G. Patel, Mr. Hasmukhbhai I.Patel, Mrs. Hansaben A.Patel, Mrs. Jivtiben C.Patel, Mrs. Jiviben T.Patel and Mrs. Lilaben T. Patel as partners, with its main object of manufacturing pharmaceutical formulations. The business was started in Naroda G.I.D.C estate. Further on 9.12.81, Mr.Mihir V. Patel, Mr.Maheshbhai M.Patel, Mr.Yogeshkumar I. Patel and Mrs.Madhuben V.Patel were admitted as Partners. The firm was carrying on its business by getting its products manufactured on Loan and Licence Basis from 1979 to 1982. All the partners decided and agreed vide resolution dated 30.10.94 that all members of Co-partnership should register the said firm as public limited company for sake of smooth working, better and effective management and improvement and advancement of business. It was also decided as per the said resolution that such company should carry Out and continue the existing business of the firm. As a result, an the incorporation of the Company on 20th January 1995, all the properties of the firm (movable & immovable) and all the liabilities of the firm 55 an the closing of the business of the day proceeding the date of incorporation of the Company vested in the Company. Since, date of incorporation of the Company i.e, 20th January 1995, all the assets and liabilities, aforesaid as on 19th January 1995, vested in the Company. Company is carrying on running business of erstwhile M/s. Lincoln Pharmaceuticals having its formulations production facilities at Naroda, GIDC, Ahmedabad, Gujarat, of manufacturing tablets, capsules, liquid and powder syrups and ointments. Company is also getting its products manufactured on "Loan and License" basis from other manufacturers to meet the demand of small volume parenterals. The Company has now decided to establish modern formulations manufacturing plant at Village: Khatraj. Tal:Kalol, Olaf. Mehsana in Gujarat to manufacture small volume parenterals like Dry powder injectables, liquid vial, liquid ampoules and eye drops and expand its production capacities of manufacturing tablets, capsules, liquid/powder syrups and ointment and also to establish fully equipped laboratory to undertake in house testing of its products for better quality control and give thrust on Research and Development. Company has already acquired N.A land Adm: 8833 Sq. Mtrs. and is in the process of acquiring further land adm. aprox.11,170 Sq.Mtrs. Company has given advance for booking cement and steel and are preparing to commence construction of factory building at new site. Company has identified all plant and machineries and has also given advance to major plant & machinery suppliers far those machineries which has longer delivery period, so as to implement the project an time. The company has existing manufacturing facilities at Naroda and if is already selling its products all over India and is having thrust in the markets of Gujarat, Rajasthan, Andhra Pradesh, Bihar and Jammu. 2000 - The company has signed agreements with NSDL & CDSL for dematerialisation. 2003 - The Joint Director of General Govt of India has given the certificate of recognition of Export House to the company. -Lincoln Pharmaceuticals introduces AIDS Drugs -Launched US FDA approved drug Gatifloxacin. -Launched PROLIN - NATURAL -Lincoln Pharmaceuticals Ltd has informed that it has launched a new drug under the brand name of 'Namsafe'. - Lincoln Pharmaceuticals Ltd has delists equity shares from Delhi Stock Exchange Association Ltd 2005 -Lincoln Pharmaceuticals secures export order from England, UK 2006 -Lincoln Pharma introduces Nozzled Liquid formulations -Lincoln Pharmaceuticals secures order from Republic Democratic of Congo -Lincoln Pharmaceuticals introduces Vivian Roll On in Novel Drug Delivery System -The Company has signed agreement with Russian firm M/s. Fortune Impex Ltd for marketing Company's manufactured products in Russia. -Company has splits its Face value of Shares from Rs 10 to Rs 2 2007 -Lincoln Pharmaceuticals recommends final Dividend @ 12% 2008 -Lincoln Pharmaceuticals recommends final Dividend @ 12% 2009 -Lincoln Pharmaceuticals has incorporated new Company namely M/s. Zullinc Healthcare Ltd as wholly owned subsidiary Company of Lincoln Pharmaceuticals Ltd. -Company has Consolidates its Face value of Shares from Rs 2 to Rs 10 2010 -Lincoln Pharmaceuticals Ltd. gains market share with technologically advanced Collagen Bio-tech products 2011 -Lincoln Pharmaceuticals wins patent for a Novel Nasal Drug delivery system introduces India's first Nasal Spray treatment for Vomiting. -Lincoln Pharmaceuticals Ltd. introduces India's first Long-Acting Paracetamol 'Pa-12' for Long term relief from Fever and Pain -Lincoln Pharmaceuticals Ltd launches Antimalarial drug 'ARH 1' developed with innovative dose optimization technology, for the first time in the world. -Lincoln Pharmaceuticals Ltd. launches Ayurvedic Product 'ISL Granules' to serve mother and child healthcare segment. -Lincoln Pharmaceuticals has acquired / purchased 62 Lacs equity shares of M/s. Lincoln Parenteral Ltd and by virtue of said acquisition / purchase of equity share, M/s. Lincoln Parenteral Ltd has become subsidiary Company 2012 -Lincoln Pharmaceuticals has recommended the payment of Dividend @ Rs. 0.60/- per equity share (6%) on face value of Rs. 10/- each 2013 -Lincoln Pharmaceuticals has recommended the payment of Dividend of Rs. 0.60 (@ 6%) per equity share of face value Rs. 10/- each. 2014 -"Lincoln Pharmaceuticals Ltd has launched an Ultramodern State of Art plant for Injectable". -Company has commended the payment of Dividend of Rs. 0.60/- per equity share (@ 6%) of face value of Rs. 10/- each of the Company. 2015 -The company has successfully launched a cough syrup called Namcold DX which contains Dextromethorphan Polistrirex. 2016 -"Lincoln Pharmaceuticals launches Vaginal Spray for "FIRST TIME IN INDIA". 2020 - Lincoln Pharma gets Gujarat food & drug regulator nod to manufacture COVID-19 drugs. =The company has received approval from the state regulator to manufacture varied dosages of HCQ tablets and HCQ sulfate tablets among others at Khatraj plant. 2021 -The company eceived approval for the company's manufacturing facility from Australia's medicines and medical devices regulator.

The Company was incorporated as a public limited company by converting partnership concern M/s. Lincoln Pharmaceuticals under Part IX of the Companies Act 1956. M/s.Lincoln Pharmaceuticals was established as a partnership firm on 18th January 1979 with Mr. Rajni G. Patel, Mr. Hasmukhbhai I.Patel, Mrs. Hansaben A.Patel, Mrs. Jivtiben C.Patel, Mrs. Jiviben T.Patel and Mrs. Lilaben T. Patel as partners, with its main object of manufacturing pharmaceutical formulations. The business was started in Naroda G.I.D.C estate. Further on 9.12.81, Mr.Mihir V. Patel, Mr.Maheshbhai M.Patel, Mr.Yogeshkumar I. Patel and Mrs.Madhuben V.Patel were admitted as Partners. The firm was carrying on its business by getting its products manufactured on Loan and Licence Basis from 1979 to 1982. All the partners decided and agreed vide resolution dated 30.10.94 that all members of Co-partnership should register the said firm as public limited company for sake of smooth working, better and effective management and improvement and advancement of business. It was also decided as per the said resolution that such company should carry Out and continue the existing business of the firm. As a result, an the incorporation of the Company on 20th January 1995, all the properties of the firm (movable & immovable) and all the liabilities of the firm 55 an the closing of the business of the day proceeding the date of incorporation of the Company vested in the Company. Since, date of incorporation of the Company i.e, 20th January 1995, all the assets and liabilities, aforesaid as on 19th January 1995, vested in the Company. Company is carrying on running business of erstwhile M/s. Lincoln Pharmaceuticals having its formulations production facilities at Naroda, GIDC, Ahmedabad, Gujarat, of manufacturing tablets, capsules, liquid and powder syrups and ointments. Company is also getting its products manufactured on "Loan and License" basis from other manufacturers to meet the demand of small volume parenterals. The Company has now decided to establish modern formulations manufacturing plant at Village: Khatraj. Tal:Kalol, Olaf. Mehsana in Gujarat to manufacture small volume parenterals like Dry powder injectables, liquid vial, liquid ampoules and eye drops and expand its production capacities of manufacturing tablets, capsules, liquid/powder syrups and ointment and also to establish fully equipped laboratory to undertake in house testing of its products for better quality control and give thrust on Research and Development. Company has already acquired N.A land Adm: 8833 Sq. Mtrs. and is in the process of acquiring further land adm. aprox.11,170 Sq.Mtrs. Company has given advance for booking cement and steel and are preparing to commence construction of factory building at new site. Company has identified all plant and machineries and has also given advance to major plant & machinery suppliers far those machineries which has longer delivery period, so as to implement the project an time. The company has existing manufacturing facilities at Naroda and if is already selling its products all over India and is having thrust in the markets of Gujarat, Rajasthan, Andhra Pradesh, Bihar and Jammu. 2000 - The company has signed agreements with NSDL & CDSL for dematerialisation. 2003 - The Joint Director of General Govt of India has given the certificate of recognition of Export House to the company. -Lincoln Pharmaceuticals introduces AIDS Drugs -Launched US FDA approved drug Gatifloxacin. -Launched PROLIN - NATURAL -Lincoln Pharmaceuticals Ltd has informed that it has launched a new drug under the brand name of 'Namsafe'. - Lincoln Pharmaceuticals Ltd has delists equity shares from Delhi Stock Exchange Association Ltd 2005 -Lincoln Pharmaceuticals secures export order from England, UK 2006 -Lincoln Pharma introduces Nozzled Liquid formulations -Lincoln Pharmaceuticals secures order from Republic Democratic of Congo -Lincoln Pharmaceuticals introduces Vivian Roll On in Novel Drug Delivery System -The Company has signed agreement with Russian firm M/s. Fortune Impex Ltd for marketing Company's manufactured products in Russia. -Company has splits its Face value of Shares from Rs 10 to Rs 2 2007 -Lincoln Pharmaceuticals recommends final Dividend @ 12% 2008 -Lincoln Pharmaceuticals recommends final Dividend @ 12% 2009 -Lincoln Pharmaceuticals has incorporated new Company namely M/s. Zullinc Healthcare Ltd as wholly owned subsidiary Company of Lincoln Pharmaceuticals Ltd. -Company has Consolidates its Face value of Shares from Rs 2 to Rs 10 2010 -Lincoln Pharmaceuticals Ltd. gains market share with technologically advanced Collagen Bio-tech products 2011 -Lincoln Pharmaceuticals wins patent for a Novel Nasal Drug delivery system introduces India's first Nasal Spray treatment for Vomiting. -Lincoln Pharmaceuticals Ltd. introduces India's first Long-Acting Paracetamol 'Pa-12' for Long term relief from Fever and Pain -Lincoln Pharmaceuticals Ltd launches Antimalarial drug 'ARH 1' developed with innovative dose optimization technology, for the first time in the world. -Lincoln Pharmaceuticals Ltd. launches Ayurvedic Product 'ISL Granules' to serve mother and child healthcare segment. -Lincoln Pharmaceuticals has acquired / purchased 62 Lacs equity shares of M/s. Lincoln Parenteral Ltd and by virtue of said acquisition / purchase of equity share, M/s. Lincoln Parenteral Ltd has become subsidiary Company 2012 -Lincoln Pharmaceuticals has recommended the payment of Dividend @ Rs. 0.60/- per equity share (6%) on face value of Rs. 10/- each 2013 -Lincoln Pharmaceuticals has recommended the payment of Dividend of Rs. 0.60 (@ 6%) per equity share of face value Rs. 10/- each. 2014 -"Lincoln Pharmaceuticals Ltd has launched an Ultramodern State of Art plant for Injectable". -Company has commended the payment of Dividend of Rs. 0.60/- per equity share (@ 6%) of face value of Rs. 10/- each of the Company. 2015 -The company has successfully launched a cough syrup called Namcold DX which contains Dextromethorphan Polistrirex. 2016 -"Lincoln Pharmaceuticals launches Vaginal Spray for "FIRST TIME IN INDIA". 2020 - Lincoln Pharma gets Gujarat food & drug regulator nod to manufacture COVID-19 drugs. =The company has received approval from the state regulator to manufacture varied dosages of HCQ tablets and HCQ sulfate tablets among others at Khatraj plant. 2021 -The company eceived approval for the company's manufacturing facility from Australia's medicines and medical devices regulator.

Read More

Parent Organisation

Lincoln Pharmaceuticals Ltd.

Founded

20/01/1995

Managing Director

Mr.Mahendra G Patel

NSE Symbol

LINCOLNEQ

FAQ

The current price of Lincoln Pharmaceuticals Ltd is ₹ 582.65.

The 52-week high for Lincoln Pharmaceuticals Ltd is ₹ 605.20 and the 52-week low is ₹ 576.90.

The market capitalization of Lincoln Pharmaceuticals Ltd is currently ₹ 1167.03. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Lincoln Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Lincoln Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Lincoln Pharmaceuticals Ltd shares.

The CEO of Lincoln Pharmaceuticals Ltd is Mr.Mahendra G Patel, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT